Shares of Abbott Laboratories Inc. (NYSE:ABT) moved higher in Monday’s premarket session after the company unveiled new clinical data supporting the effectiveness of its technologies designed to treat abnormal heart rhythms, particularly atrial fibrillation (AFib).
The positive movement released on Saturday follows the release of new data from several clinical trials, highlighting the effectiveness of Abbott’s devices.
FlexPulse Study Shows High Success And Safety Rates
New six-month findings from the FlexPulse IDE study provided early evidence supporting Abbott’s TactiFlex Duo Ablation Catheter, Sensor Enabled, in treating complex AFib cases. The data also reinforced results previously observed in the CE Mark study.
The 188-patient study showed that 87% of participants remained free from documented arrhythmias at six months. The device also demonstrated a strong safety profile, with 98.3% of patients experiencing no major safety events.
Additionally, 93.3% of patients were successfully treated using pulsed field ablation (PFA) alone, indicating that this energy source was sufficient even in complex cases.
Physicians were able to efficiently complete procedures, with 93.9% of patients not requiring a second ablation.
Pacing And Defibrillation Trials Highlight Strong Performance
Abbott also shared results from two clinical trials evaluating its investigational leadless and traditional pacing and defibrillation technologies designed for left bundle branch pacing (LBBP).
This approach aims to better replicate the heart’s natural electrical activity.
The trials demonstrated a 99% success rate in achieving left bundle branch area pacing (LBBAP), while a stricter benchmark showed an 86% success rate for LBBP or likely LBBP.
Physicians required fewer than one repositioning attempt per patient on average.
Defibrillation outcomes were equally strong, with a 100% success rate and 92.5% of cases achieving first shock success at 20 joules.
No patients needed lead repositioning, and electrical performance remained stable over three months without inappropriate therapies.
ABT Stock Price Activity: Abbott Laboratories shares were up 0.11% at $91.23 during premarket trading on Monday, according to Benzinga Pro data.
Photo by greenbutterfly via Shutterstock
Recent Comments